Abstract
The Lymphoma Partnering 2007-2013 report provides understanding and access to
the lymphoma partnering deals and agreements entered into by the worlds
leading healthcare companies.
- Trends in lymphoma partnering deals
- Top lymphoma deals by value
- Deals listed by company A-Z, industry sector, stage of development,
technology type
The Lymphoma Partnering 2007-2013 provides understanding and access to the
lymphoma partnering deals and agreements entered into by the worlds leading
healthcare companies.
The report provides an analysis of lymphoma partnering deals. The majority of
deals are discovery or development stage whereby the licensee obtains a right
or an option right to license the licensors lymphoma technology. These deals
tend to be multicomponent, starting with collaborative R&D, and
commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals
terms provides critical insight into the negotiation process in terms of what
you can expect to achieve during the negotiation of terms. Whilst many smaller
companies will be seeking details of the payments clauses, the devil is in the
detail in terms of how payments are triggered - contract documents provide
this insight where press releases do not.
This data driven report contains over 100 links to online copies of actual
lymphoma deals and contract documents as submitted to the Securities Exchange
Commission by companies and their partners, where available. Contract
documents provide the answers to numerous questions about a prospective
partner's flexibility on a wide range of important issues, many of which will
have a significant impact on each party's ability to derive value from the
deal.
The initial chapters of this report provide an orientation of lymphoma
partnering trends.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an
overview of the trends in lymphoma partnering since 2007, including a summary
of deals by industry sector, stage of development, deal type, and technology
type. Numerous tables provide outline financial trends.
Chapter 3 provides an overview of the leading lymphoma deals since 2007. Deals
are listed by headline value, signed by bigpharma, most active bigpharma.
Where the deal has an agreement contract published at the SEC a link provides
online access to the contract.
Chapter 4 provides a comprehensive directory of lymphoma partnering deals
signed and announced since 2007. The chapter is organized by company A-Z,
stage of development at signing, deal type (collaborative R&D, co-promotion,
licensing etc), and technology type. Each deal title links via Weblink to an
online version of the deal record, and where available the contract document,
providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs
to know about partnering in the research, development and commercialization of
lymphoma technologies and products.
Report scope
Lymphoma Partnering 2007-2013 is intended to provide the reader with an
in-depth understanding and access to lymphoma trends and structure of deals
entered into by leading companies worldwide.
This data driven report includes:
- Trends in lymphoma dealmaking in the biopharma industry since 2007
- Access to summary headline, upfront, milestone and royalty data
- Access to over 100 lymphoma contract documents
- The leading lymphoma deals by value since 2007
In Lymphoma Partnering 2007-2013, the available deals are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Company A-Z
- Industry sector
- Stage of development at signing
- Deal component type
- Technology type
Each deal title links via Weblink to an online version of the deal record and
where available, the contract document, providing easy access to each contract
document on demand.
Benefits
Lymphoma Partnering 2007-2013 provides the reader with the following key
benefits:
- In-depth understanding of lymphoma deal trends since 2007
- Access to summary headline, upfront, milestone and royalty data
- Comprehensive access to over 100 actual lymphoma deals entered into by the
world's biopharma companies since 2007
- Insight into key deal terms included in contracts, where disclosed
- Understand the key deal terms companies have agreed in deals
- Undertake due diligence to assess suitability of your proposed deal terms
for partner companies
About Current Partnering
Current Partnering was established in 2007 and has become the leading publisher of deal term reports within the life sciences. Designed to translate research into commercial success, Current Partnering provides an opportunity for the dissemination of the latest trends in partnering activity across the life sciences.
Current Partnering report titles cover all aspects of partnering best practice and deal terms, providing users with the information and insight required to optimise their partnering activities.
Current Partnering is a trademark of Wildwood Ventures Ltd..
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in lymphoma partnering
- 2.1. Introduction
- 2.2. Lymphoma partnering over the years
- 2.3. Bigpharma lymphoma dealmaking activity
- 2.4. Lymphoma partnering by deal type
- 2.5. Lymphoma partnering industry sector
- 2.6. Lymphoma partnering by stage of development
- 2.7. Lymphoma partnering by technology type
- 2.8. Disclosed financial deal terms for lymphoma partnering
- 2.8.1. Lymphoma headline values
- 2.8.2. Lymphoma upfront payments
- 2.8.3. Lymphoma milestone payments
- 2.8.4. Lymphoma royalty rates
Chapter 3 - Leading lymphoma deals
- 3.1. Introduction
- 3.2. Top lymphoma deals by value
- 3.3. Top lymphoma deals involving bigpharma
Chapter 4 - Dealmaking directory
- 4.1. Introduction
- 4.2. Company A-Z
- 4.3. By deal type
- Asset purchase
- Bigpharma outlicensing
- Co-development
- Collaborative R&D
- Co-market
- Contract service
- Co-promotion
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Settlement
- Spin out
- Sub-license
- Supply
- Termination
- 4.4. By industry sector
- Academic
- Bigpharma
- Biotech
- Drug delungy
- Medical device
- Diagnostic
- Generic pharma
- Government
- Non-profit
- Pharmaceutical
- Research tools
- Services
- Specialty pharma
- 4.5. By stage of development
- Discovery
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Registration
- Marketed
- 4.6. By technology type
- Analysis
- Animal models
- Assays
- Bioinformatics
- Biological compounds
- Biomarkers
- Biomaterials
- Cell culture
- Cell therapy
- Clinical testing
- Diagnostic - companion
- Devices
- Diagnostics
- Discovery tools
- DNA probes
- Drug delungy
- Enabling technology
- Epigenetics
- Equipment
- Facilities
- Gene therapy
- Genomics
- Imaging
- Industrial chemicals
- In vitro models
- Monoclonal antibodies
- Nanotechnology
- Oligonucleotide
- Peptides
- Personalised medicine
- Processes
- Proteomics
- Radio/Chemo-therapy
- Recombinant DNA
- Research services
- Research supplies
- RNA therapeutics
- Screening
- Small molecules
- Stem cells
- Vaccines
Chapter 5 - Partnering resource center
- 5.1. Online partnering
- 5.2. Partnering events
- 5.3. Further reading on dealmaking
Appendices
- Appendix 1 - Deal type definitions
- About Wildwood Ventures
- Current Partnering
- Current Agreements
- Recent titles from CurrentPartnering
- Order Form - Reports
Table of figures
- Figure 1: lymphoma partnering since 2007
- Figure 2: Bigpharma - top 50 - lymphoma deals 2007 to 2013
- Figure 3: Bigpharma lymphoma deal frequency - 2007 to 2013
- Figure 4: Lymphoma partnering by deal type since 2007
- Figure 5: Lymphoma partnering by industry sector since 2007
- Figure 6: Lymphoma partnering by stage of development since 2007
- Figure 7: Lymphoma partnering by technology type since 2007
- Figure 8: Lymphoma deals with a headline value
- Figure 9: Lymphoma deals with upfront payment values
- Figure 10: Lymphoma deals with milestone payments
- Figure 11: Lymphoma deals with royalty rates, %
- Figure 12: Top lymphoma deals by value since 2007
- Figure 13: Top lymphoma deals signed by bigpharma value since 2007
- Figure 14: Online partnering resources
- Figure 15: Forthcoming partnering events
- Figure 16: Deal type definitions
